Mandate

Vinge advises industrifonden in connection with pharmalink’s capital raising of sek 96 million

October 08, 2013

Industrifonden and the Norwegian investment company, Investinor have invested a combined total of SEK 79 million in Pharmalink, the pharmaceuticals development company. Private investors have also contributed to the total capital raising of SEK 96 million. The funds will be used to further develop Pharmalink’s product portfolio.

Pharmalink is a pharmaceuticals company which improves and further develops existing pharmaceuticals. The company is currently conducting the Nefecon project for the treatment of inflammation of the kidneys and the Busulipo project for treatment prior to bone marrow transplantation.

Industrifonden has been a stakeholder in Pharmalink since 2004. The Norwegian investment company, Investinor is a new stakeholder.

Vinge partner Johan Larsson advised Industrifonden

Related

Vinge advises EQT in connection with the sale of Eton

Vinge has advised EQT VII in connection with its sale of Eton to a consortium of private investors.
July 01, 2025

Vinge advises Triton in connection with the acquisition of Prenax

Vinge has advised Triton Smaller Mid Cap Fund II in connection with the acquisition of Prenax from LBO France and certain minority shareholders.
July 01, 2025

Vinge advises Impilo on the establishment of Impilo Healthcare

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Healthcare. The fund will have EUR 320m in commitments.
July 01, 2025